Zosano Pharma, Inc. Appoints Winnie W. Tso, CPA As Chief Financial Officer

FREMONT, Calif., June 2, 2014 /PRNewswire/ -- Zosano Pharma, Inc., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, today announced the appointment of Winnie W. Tso, CPA, as Chief Financial Officer. With more than 15 years of finance, accounting and strategic management experience in the biotechnology and pharmaceutical industries, Ms. Tso brings a great track record of successful financing transactions and public-company accounting to Zosano. Ms. Tso will report to Mr. Vikram Lamba, Zosano's President and Chief Executive Officer.

"We are thrilled to have Winnie, an accomplished accounting and finance executive, join Zosano," said Mr. Lamba. "Her deep knowledge of accounting management in the life sciences industry and her prior experience in financial reporting duties for publicly traded companies are great assets to have on our leadership team."

Prior to joining Zosano, Ms. Tso was Vice President, Finance and Corporate Controller of SciClone Pharmaceuticals, Inc., a publicly traded specialty biopharmaceutical company in Foster City, California. Prior to that, Ms. Tso held vice president and principal accounting officer positions from 2009 to 2013, including at Velti plc where she helped lead the company's U.S. public offering, raising in excess of $150 million in equity financing. Previously, Ms. Tso held senior finance positions at several publicly traded biopharmaceutical companies, including ARYx Therapeutics, Titan Pharmaceuticals and Genelabs Technologies, where she was responsible for building the finance and accounting infrastructures and implementing systems of internal controls. Ms. Tso is a Certified Management Accountant, a Certified Financial Manager, a Certified Public Accountant licensed in the State of California, and a member of the American Institute of Certified Public Accountants. Ms. Tso received her B.S. degree in Business Administration from the Haas School of Business at the University of California, Berkeley.

About Zosano Pharma

Zosano Pharma, Inc. is a privately held biopharmaceutical company and a pioneer in the field of transdermal drug delivery. Zosano is developing products using its proprietary microneedle patch system. Zosano seeks to develop products with significant commercial potential both independently and in collaboration with strategic partners. Zosano's microneedle patch delivers therapeutic compounds through the skin and provides rapid systemic drug delivery in a convenient, needlefree and painfree system. Zosano's microneedle patch system has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.

SOURCE Zosano Pharma, Inc.